40
Participants
Start Date
December 18, 2015
Primary Completion Date
December 30, 2016
Study Completion Date
December 30, 2016
Liraglutide
Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
Placebo
Mayo Clinic in Rochester, Rochester
Lead Sponsor
Collaborators (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Novo Nordisk A/S
INDUSTRY
Mayo Clinic
OTHER